Project Grant R01CA314059
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $585K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- Federal Project Grant Award Summary New York University School of Medicine received a $695,852 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on May 1, 2026, with a completion date of April 30, 2031. The award funds fundamental research investigating T cell circuits in the lymphatic system during melanoma progression, specifically examining tumor-draining lymph nodes (TDLNs) as key immune surveillance hubs. The research...
- Federal Grant Award Summary New York University School of Medicine received a $716,681 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 22, 2026 through April 30, 2031. This award supports fundamental research aimed at understanding and developing therapeutic interventions for myeloid sarcoma (MS), a rare extramedullary subtype of acute myeloid leukemia affecting approximately 5-10% of AML patients. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded New York University School of Medicine a $2,013,199 Project Grant effective September 1, 2025, through November 30, 2029, under the Cancer Treatment Research program (CFDA 93.395). This award supports the expansion of NCI-sponsored clinical research in hematologic malignancies to Brooklyn and Queens through the Perlmutter Cancer Center (PCC). The PCC will oversee a robust portfolio of clinical trials across national networks...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $642,242 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai to investigate the mechanisms driving brain metastasis in breast cancer models. The award, effective May 15, 2026, through April 30, 2031, supports fundamental research aimed at understanding how Neuregulin 3 (NRG3), a neuron-associated ligand, promotes the transition of cancer cells from bone...
- Federal Project Grant Award Summary New York University School of Medicine received a $315,246 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective August 1, 2025, through July 31, 2030. This five-year research initiative, titled "Breaking Cytokine Loops in Lung Adenocarcinoma," will deliver fundamental cancer research and scientific investigation focused on understanding immune resistance mechanisms in lung cancer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $102,984 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on December 25, 2025, under the Cancer Research Manpower program (CFDA 93.398). The award, with an ultimate completion date of June 30, 2028, supports research titled "Spatiotemporal Resolution of Niche and Genomic Co-Evolution in Brain-Metastatic Organotropism." The project aims to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $2.69 million Project Grant under the Cancer Biology Research program (CFDA 93.396) on September 24, 2025, with completion scheduled for August 31, 2029. This award supports fundamental research investigating the mechanisms and impact of Neuregulin 3 (NRG3) induction in bone metastasis of breast cancer. The project will employ molecular and genetic approaches to...
- Federal Project Grant Award Summary New York University School of Medicine received a $149,190 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective December 1, 2025, with completion anticipated by May 6, 2027. This award supports investigator-initiated biomedical research training and research career development activities in cancer research aligned with the National Cancer Program's strategic priorities. The research project...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $510,431 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2025 through June 30, 2030. This award supports fundamental research investigating the mechanisms of metastatic recurrence and therapeutic resistance in melanoma, with particular emphasis on understanding how aging influences tumor dormancy and the microenvironment. The research examines Wnt signaling...